As I consult with clients, I see that technology will ultimately be the driver behind pharmaceutical and biotechnology advancements in the coming decade. I believe that the use of artificial intelligence (AI) is a prime example of innovative efficiencies to come.
More than 15 years ago, when I was leading the arthritis therapeutic area at Searle/Monsanto and striving to get Celebrex to market as the first cox-2 inhibitor, pharmaceutical development was at an evolutionary stage. Manual processes were improving, but great strides in efficiencies were still…
G. Steven Geis, Ph.D., M.D., Co-Founder, ClinGenuity Partner, Geis-Hides Consulting LLC. ClinGenuity’s mission is to significantly reduce time and increase accuracy in study reporting processes for sponsor-based clinical trials, helping to accelerate the availability of important medicines to patients in need. For more information, visit clingenuity.com.